| Biomarker ID | 1506 |
| PMID | 25139197 |
| Year | 2014 |
| Biomarker | p2PSA |
| Biomarker Basis | Concentration Based (pg/mL) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in patients with Grade pT3 or GS ≥ 7 |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate: HR= 0.02 (0.01–0.03), p-value= 0.001, AUC: 0.65 (0.59–0.70); Multivariate: HR= -0.01 (0.02 to 0.00), p-value = 0.047 |
| Effect on Pathways | NA |
| Experiment | Both adverse pathologic characteristics (pT3 disease and pathologic Gleason score I7) |
| Type of Biomarker | Prognostic |
| Cohort | The study cohort consisted of 489 patients with biopsy-proven clinically localised PCa who underwent either open or robot-assisted laparoscopic RP. 134 had stage pT3 and 336 had Gleason Score ≥ 7 |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.62 (95% CI: 0.57–0.68) |
| Accuracy | NA |
| Level Of Significance | p < 0.001 |
| Method Used | UniCel DxI800 Immunoassay System analyser |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |